Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ant Uzay

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|October 14, 2025
BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life ExperienceAnt Uzay, Elif Şenocak Taşçı, Yasemin Gündoğdu, et al.
The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 3, 2025
Does body mass index affect stem cell yield in healthy donors?Seda Yilmaz, Nazik Okumus, Mert Seyhan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 8, 2025
Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?Yavuz Katircilar, Abdulkadir Sahin, Muruvvet Seda Aydin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 21, 2025
The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantationHikmetullah Batgi, Tuğba Zorlu, Mehmet Ali Erkurt, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 8, 2025
A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myelomaAbdullah Karakus, Ugur Hatipoglu, Yavuz Katircilar, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 24, 2025
The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomesBurcu Aslan Candir, Nazik Okumus, Ipek Yonal Hindilerden, et al.
Annals of Hematology|November 19, 2022
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from TurkeyMehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, et al.
Hematological Oncology|May 22, 2023
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world dataElif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|October 14, 2025
BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life ExperienceAnt Uzay, Elif Şenocak Taşçı, Yasemin Gündoğdu, et al.
The New England Journal of Medicine|July 14, 2021
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseRobert Zeiser, Nicola Polverelli, Ron Ram, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 3, 2025
Does body mass index affect stem cell yield in healthy donors?Seda Yilmaz, Nazik Okumus, Mert Seyhan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 8, 2025
Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?Yavuz Katircilar, Abdulkadir Sahin, Muruvvet Seda Aydin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyRobert Zeiser, Domenico Russo, Ron Ram, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 21, 2025
The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantationHikmetullah Batgi, Tuğba Zorlu, Mehmet Ali Erkurt, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|July 8, 2025
A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myelomaAbdullah Karakus, Ugur Hatipoglu, Yavuz Katircilar, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 24, 2025
The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomesBurcu Aslan Candir, Nazik Okumus, Ipek Yonal Hindilerden, et al.
Annals of Hematology|November 19, 2022
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from TurkeyMehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, et al.
Hematological Oncology|May 22, 2023
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world dataElif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, et al.
Pageof 3